Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?
about
Study exploring depression and cardiovascular diseases amongst Arabic speaking patients living in the State of Qatar: Rationale and methodologyCardiovascular considerations in antidepressant therapy: an evidence-based reviewDual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsPathophysiology of Heart Failure.Central 5-HT1A receptor-mediated modulation of heart rate dynamics and its adjustment by conditioned and unconditioned fear in mice.An analysis of QTc prolongation with atypical antipsychotic medications and selective serotonin reuptake inhibitors using a large ECG record database.Mindfulness-based cognitive therapy for inflammatory bowel disease patients: findings from an exploratory pilot randomised controlled trial.Cardiovascular safety profile of dapoxetine during the premarketing evaluation.Sudden death of cardiac origin and psychotropic drugsGene expression profile analysis of genes in rat hippocampus from antidepressant treated rats using DNA microarrayAugmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study.Prevalence of antidepressant prescription or use in patients with acute coronary syndrome: a systematic review.Effects of antidepressants on IP-10 production in LPS-activated THP-1 human monocytes.Fluoxetine blocks Nav1.5 channels via a mechanism similar to that of class 1 antiarrhythmics.Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010.A consensus statement for safety monitoring guidelines of treatments for major depressive disorder.Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster.Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): a search for new dual-acting agents as potential antidepressants.Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.Effects of citalopram on heart rate variability in women with generalized anxiety disorderCardiologic side effects of psychotropic drugs.19q13.11 cryptic deletion: description of two new cases and indication for a role of WTIP haploinsufficiency in hypospadiasHBK-14 and HBK-15 Do Not Influence Blood Pressure, Lipid Profile, Glucose Level, or Liver Enzymes Activity after Chronic Treatment in RatsEvaluation of the Anxiolytic and Antidepressant Activities of the Aqueous Extract from Camellia euphlebia Merr. ex Sealy in Mice.Concomitant medication of psychoses in a lifetime perspective.5-hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT).Quetiapine: efficacy, tolerability and safety in schizophrenia.Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective.Panic attacks and supraventricular tachycardias: the chicken or the egg?Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis.New cell models and assays in cardiac safety profiling.Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN.The use of mindfulness-based cognitive therapy for improving quality of life for inflammatory bowel disease patients: study protocol for a pilot randomised controlled trial with embedded process evaluation.Effect of depression and sertraline treatment on cardiac function in female nonhuman primatesPaliperidone: As a Possible Cause of Pericardial EffusionA topographical map of the causal network of mechanisms underlying the relationship between major depressive disorder and coronary heart disease.Serotonin: from top to bottom.Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events.The effects of fall-risk-increasing drugs on postural control: a literature review.The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy.
P2860
Q26825298-AC985AF0-B922-4F3E-9A96-FC7BBCDD0F50Q27021843-20A82BCF-E193-4D83-BD28-EAE2A7E4853EQ28305100-7BB5058D-3EBE-465A-A278-60C85271571DQ30315815-9F679E19-7343-4983-8001-D857EEB8153DQ30429534-78430778-5FE5-4AA3-8426-18B3240DF6EDQ30489429-9231066A-08F8-4A6C-BC62-D6EE031AC0DBQ30662409-769DA5B2-2539-42B1-98B0-5B76554F5B66Q33159832-82C17DA3-3D2E-4886-8684-7B9D478CE84FQ33161295-6EEE85AC-A221-4C79-AC9C-F13C60268B1FQ33759011-50B7BB71-4816-4E7C-BF29-47F3D2381757Q34002264-0C537C69-1DBA-4AC9-B20E-4408F74174D4Q34087791-51061A3B-1211-4750-A871-12ED60CF3C85Q34158301-21D6FF70-530D-43D8-AF8B-BCFD921EAF76Q34186050-843BE2B7-7CB3-4A23-BC4A-062B94387475Q35178973-66807705-54EA-49EC-8A44-57D5A8622F3DQ35311467-B65CB987-6089-4F7D-AB50-00FDFAF3F85FQ35529642-51FC0C79-8080-4D77-A1EF-E8D9E65C452FQ35992330-6DC7D79B-57AE-4E75-91B5-67F44F5BDB6FQ36054408-5DF3712A-E794-4F24-B579-AC4C58032870Q36055357-CE1F8BBF-6669-4236-A9EB-F2BAF414F097Q36077336-12081A19-AD05-4F8D-A504-8C3F4B0EBB71Q36105203-C5B46590-35F0-4E41-860D-5D0B9CCCDC7AQ36176479-51CD50BF-B43D-42DC-BC03-2CC62A9F4CB1Q36249522-28A39F39-CE64-4BD1-AAF2-36C6BCACC1A7Q36420453-05D9A230-F09B-4DA7-91B6-E9BA703EBDA5Q36514263-6929A968-97BC-4236-A3C2-179BDBB6214EQ36532142-970C6781-C60E-4718-A998-56B9E367F587Q36536709-FFE6D337-6918-4158-85D2-D5AE097FFB79Q36540750-F56456FD-D106-4CA8-BC69-67698AFA5E0FQ36576591-4E2FEFBE-5024-49A8-BA27-550573DA741FQ36909315-63F47B4D-CEB3-4357-AFC8-E03662D3BF07Q37197187-8F2F491B-1A9E-4CDE-AC82-619EB2667547Q37426522-E8B22155-A46B-4F9F-916D-6E0033AF4C85Q37677026-1C340367-E9B1-4AEB-A516-FE44D904CA5DQ37703890-30C6C438-E299-4A3D-BF09-E038AAF2BDFEQ37866294-BA770DA4-7CE9-427E-AEEF-C175993315F9Q38055710-3FF3773A-6644-49A6-9303-9FC91C8C4360Q38086176-DF6F7868-99DE-4027-8CE9-4ACEBCFC7E2CQ38134320-6D0532CE-43D3-4641-A289-6B3E1045E7F4Q38154910-B4D209B4-0E9A-4053-B1C2-24154CA24A09
P2860
Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cardiovascular side effects of ...... tics: new drugs, old concerns?
@ast
Cardiovascular side effects of ...... tics: new drugs, old concerns?
@en
type
label
Cardiovascular side effects of ...... tics: new drugs, old concerns?
@ast
Cardiovascular side effects of ...... tics: new drugs, old concerns?
@en
prefLabel
Cardiovascular side effects of ...... tics: new drugs, old concerns?
@ast
Cardiovascular side effects of ...... tics: new drugs, old concerns?
@en
P2860
P356
P1476
Cardiovascular side effects of ...... tics: new drugs, old concerns?
@en
P2093
Valeria Kecskemeti
P2860
P304
P356
10.2174/1381612043383872
P50
P577
2004-01-01T00:00:00Z